Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

BMY or NVO: Which Is the Better Value Stock Right Now?

BMY vs. NVO: Which Stock Is the Better Value Option?

Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum

Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.

Lilly (LLY) Launches Half-Priced Version of Humalog Insulin

Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

What's in the Cards for AEterna (AEZS) This Earnings Season?

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Why Earnings Season Could Be Great for Novo Nordisk (NVO)

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Allergan (AGN) Beat Earnings Estimates Again in Q1?

Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?

Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

Zoetis (ZTS) is expected to provide updates on the pipeline, when it reports first-quarter 2019 results on May 2.

Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?

Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.

Lannett (LCI) to Report Q3 Earnings: What's in the Cards?

Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches

Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.

What's in Store for Bayer (BAYRY) This Earnings Season?

Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.

Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

Gilead Collaborates With Insitro to Develop NASH Therapies

Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

Gilead to Collaborate with Novo Nordisk for NASH Treatment

Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.

Sangamo Rises on Positive Phase I/II Hemophilia Study Data

Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.

Kevin Cook headshot

Bull of the Day: DexCom (DXCM)

Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.